A pharma-tech focused venture capital firm, founded in 2022 and headquartered in the US, invests in early-stage companies and also has the capability to incubate new ventures. The firm is driven by the belief that the pharmaceutical industry represents a strong and scalable customer base, and seeks technologies that align with or enhance the pharma value chain. While open to global opportunities, the firm shows a preference for companies based in the United States. Typical investment sizes range from $2 million to $5 million, and the firm is flexible in its role, able to lead or follow in financing rounds.
The firm invests across a broad spectrum of pharma-tech, including technologies targeting patients or providers, tech-bio platforms, drug discovery tools, AI-driven applications, supply chain innovations, and data-centric platforms. In essence, it is interested in any innovation that contributes to the pharmaceutical and life sciences value chain. The firm is disease-agnostic in its approach.
An active investor, the firm typically takes a board seat or observer role and prefers companies that have pharmaceutical companies as at least one major customer or are built with pharma as the primary target market.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
Next Phase Newsletter 
Leave a comment